Olema Pharmaceuticals, Inc.
Public company- Headquarters
- SAN FRANCISCO, California
- Ticker
- OLMA
- CIK
- 0001750284
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| DirectorGorjan Hrustanovic | Oct 15, 2026 | Departed |
| CFOJason O’Byrne | Aug 13, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive departure
Director departs: Gorjan Hrustanovic
Gorjan Hrustanovic, Director of Olema Pharmaceuticals, Inc., resigns the role, effective October 14, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 15, 2026Role: Director
- Executive appointment
CFO appointed: Jason O’Byrne
Jason O’Byrne was named Chief Financial Officer, principal financial officer and principal accounting officer of Olema Pharmaceuticals, Inc., effective August 11, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 13, 2026Role: Chief Financial Officer, principal financial officer and principal accounting officer
Last verified Nov 8, 2026